Medical devices, healthcare technology and the business of care
PMA approval · P030031

BIOSENSE WEBSTER NAVISTAR/CELSIUS THERMO COOL DIAGNOSTIC/ABLATION DEFLECTABLE TIP CATHETERS

Biosense Webster, Inc. · Decision date Nov 5, 2004

MEDTECHLEDGER EXPLANATIONP030031

What did the FDA approve?

The November 5, 2004 approval covers the Biosense Webster Navistar/Celsius ThermoCool deflectable diagnostic/ablation catheters, including eight Navistar ThermoCool models and six Celsius ThermoCool models. The catheters are indicated for catheter-based cardiac electrophysiological mapping (stimulating and recording), and, when used with the Stockert 70 generator, for treating type I atrial flutter in patients age 18 or older.

The Navistar ThermoCool catheter also provides location information when used with the CARTO EP/XP navigation system. The source statement reports the approved purpose but does not itself establish safety or clinical effectiveness. No supplement type or reason is recorded, so the relationship to any earlier PMA scope cannot be determined from the supplied fields.

FDA approval order statement

APPROVAL FOR FOR THE NAVISTAR/CELSIUS THERMOCOOL DEFLECTABLE DIAGNOSTIC/ABLATION CATHETERS, WHICH INCLUDE THESE MODELS: NAVISTAR THERMOCOOL (MODELS NS75T-BCT-252-HS, NS75T-CCT-252-HS, NS75T-DCT-252-HS, NS75T-FCT-252-HS, NS75TC-BCT-252-HS, NS75TC-CCT-252-HS, NS75TC-DCT-252-HS, AND NS75TC-FCT-252-HS); AND CELSIUS THERMOCOOL (MODELS D7IT-BL-252-RT, D7IT-DL-252-RT, D7IT-FL-252-RT, D7ITC-BL-252-RT, D7ITC-DL-252-RT, AND D7ITC-FL-252-RT). THE BIOSENSE WEBSTER NAVISTAR/CELSIUS THERMOCOOL DIAGNOSTIC/ABLATION DEFLECTABLE TIP CATHETERS AND RELATED ACCESSORY DEVICES ARE INDICATED FOR CATHETER-BASED CARDIAC ELECTROPHYSIOLOGICAL MAPPING (STIMULATING AND RECORDING), AND WHEN USED WITH THE STOCKERT 70 GENERATOR, FOR THE TREATMENT OF TYPE I ATRIAL FLUTTER IN PATIENTS AGE 18 OR OLDER. THE NAVISTAR THERMOCOOL CATHETER PROVIDES LOCATION INFORMATION WHEN USED WITH THE CARTO EP/XP NAVIGATION SYSTEM.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Nov 5, 2004

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P030031
Regulatory pathway
Premarket approval application
Product code
OAD
Decision code
APPR
Decision date
Nov 5, 2004
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.

Product code
OAD
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P030031 received

    Application receipt date recorded by FDA.

  2. P030031 · FDA decision

    APPR

  3. P030031/S142 · Related supplement

    THERMOCOOL SMARTTOUCH SF Catheter

  4. P030031/S146 · Related supplement

    EZ STEER THERMOCOOL NAV BI-DIRECTIONAL ELECTROPHYSIOLOGY CATHETER; THERMOCOOL SMARTTOUCH BI-DIRECTIONAL NAVIGATION CATHE

Timeline entries are records held by MedtechLedger for P030031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030031

Explore the linked device profile

Other records with product code OAD

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records